logo
Share SHARE
FONT-SIZE Plus   Neg

Eli Lilly Says Dulaglutide Meets Primary Endpoint - Quick Facts

Eli Lilly and Co. (LLY) announced that dulaglutide, its investigational, long-acting glucagon-like peptide 1, or GLP-1, analog being studied as a once-weekly treatment for type 2 diabetes, met its primary endpoint of non-inferiority for mean 24-hour systolic blood pressure after 16 weeks.

According to the company, the results came from a Phase II study that compared two doses of dulaglutide to placebo, using ambulatory blood pressure monitoring to characterize changes in blood pressure and heart rate. Also, the 1.5 mg dulaglutide dose significantly reduced mean 24-hour SBP compared to placebo.

Gwen Krivi, vice president, product development, Lilly Diabetes, said, "We are very encouraged by these clinical trial results, in addition to the rest of the clinical trial data we've seen to date for dulaglutide. Dulaglutide is currently in Phase III clinical trials, where it will continue to be evaluated on its efficacy to lower blood glucose levels, overall safety, weight effects and effects on cardiovascular outcomes. We believe dulaglutide, if approved, can bring significant benefits to people with type 2 diabetes."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
British lender Lloyds Banking Group Plc. Friday reported higher profit in its first half, benefited by increased net interest income and margin as well as lower impairment. Looking ahead, the company lifted its net interest margin forecast. Amgen reported an increase in second-quarter profit, driven by sales of arthritis drug Enbrel and osteoporosis treatments Xgeva and Prolia, and improved margins. Both earnings and sales topped Wall Street estimates. Electronic Arts Inc. (EA) on Thursday reported an increase in profit for the first quarter, reflecting continued strong digital revenues, with both earnings and revenues topping Wall Street estimates. However, shares of the company fell over 4 percent, after having detailed a weak outlook. Redwood...
comments powered by Disqus
RELATED NEWS
Trade LLY now with 
Follow RTT